

## TABLE OF CONTENTS

	<b>Page</b>
ACKNOWLEDGEMENTS	iii
ABSTRACT IN ENGLISH	v
ABSTRACT IN THAI	vii
LIST OF TABLES	x
LIST OF FIGURES	xi
CHAPTER 1 INTRODUCTION	1
CHAPTER 2 REVIEW OF THE LITERATURE	7
CHAPTER 3 METHODOLOGY	32
CHAPTER 4 RESULTS	47
CHAPTER 5 DISCUSSION	58
REFERENCES	66
APPENDICES	77
CIRRICULUM VITAE	106

**LIST OF TABLES**

<b>Table</b>		<b>Page</b>
1	The proportion of antibiotics and DI water volume used for preparing a stock solution of single antibiotics	38
2	Summary of the human specific primer sets	46
3	3Mix composition	63

ลิขสิทธิ์มหาวิทยาลัยเชียงใหม่

Copyright© by Chiang Mai University  
All rights reserved

## LIST OF FIGURES

<b>Figures</b>	<b>Page</b>
1 The main objective of regenerative endodontics	8
2 The blood clot in the root canals	9
3 Histologic evidence of vascularized connective tissue grew in the root canals	10
4 Revascularization procedures	15
5 Histological study of infected immature dog's teeth	20
6 Regenerated tissue in the root canals (cementocyte)	20
7 Vital pulp-like structure regenerated after PRP treatment	21
8 Odontoblast-like cells was observed after revascularization	21
9 Anatomy of an apical papilla	24
10 Pathway of infection	25
11 The role of ALP in mineralization	27
12 Cytotoxicity of ciprofloxacin, clindamycin, and metronidazole	29
13 Detrimental effect of Three-antibiotic combinations on SCAPs	30
14 DPC viability after being treated 3Mix at different concentration	31
15 APC viability after being treated 3Mix at different concentration	31
16 Flow chart showing the steps for this experiment	33
17 Pulp tissue harvesting	35
18 Apical papilla cell harvesting	36
19 Cell extraction using enzymatic technique	37
20 Preparation of 3Mix (powder)	39

21	Preparation of 3Mix in water	39
22	Preparation of 3Mix stock solution	40
23	MTT cell proliferation assay	42
24	The alizarin red-S staining method	43
25	Alizarin red-S de-staining and quantification assay	44
26	Real time RT-PCR	46
27	Monitoring of cultured human DPCs and APCs for 3-7 days	47
28	Morphology of human DPCs and APCs	48
29	Monitoring of cultured human DPCs in differentiating media for 7, 14, and 21 days	49
30	Monitoring of cultured human APCs in differentiating media for 7, 14, and 21 days	51
31	The proliferative capacity of treated DPCs and untreated DPCs	52
32	The proliferative capacity of treated APCs and untreated APCs	53
33	Alizerin red-S disclosed DPCs after cultured in differentiating media at various time interval	54
34	The quantitative analysis of mineralized matrix formation (DPCs)	55
35	Alizerin red-S disclosed APCs after cultured in differentiating media at various time interval	55
36	The quantitative analysis of mineralized matrix formation (APCs)	56
37	Gene expression in DPCs compared to treated DPCs	57
38	Gene expression in APCs compared to treated APCs	57
39	Cell morphology of DPCs and APCs after treatment with an LC50 dose of 3Mix	62